-
1
-
2
БЕЗОПАСНОСТЬ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. КАК ОБЕСПЕЧИТЬ ПАЦИЕНТУ ОПТИМАЛЬНОЕ ЛЕЧЕНИЕ?...
Julkaistu 2014-12-01Aiheet: Hae kokoteksti
Artikkeli -
3
PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
Julkaistu 2015-09-01Aiheet: Hae kokoteksti
Artikkeli -
4
ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY
Julkaistu 2015-09-01Aiheet: Hae kokoteksti
Artikkeli -
5
РИВАРОКСАБАН ПРИ ТРОМБОЗЕ ЛЕВОГО ПРЕДСЕРДИЯ У ПАЦИЕНТА С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ПРИ ПРОВЕДЕНИИ КАТЕТЕРНОЙ АБЛЯЦИИ...
Julkaistu 2014-12-01Aiheet: Hae kokoteksti
Artikkeli -
6
PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
Julkaistu 2015-09-01Aiheet: “…новые пероральные антикоагулянты…”
Hae kokoteksti
Artikkeli -
7
-
8
THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER
Julkaistu 2015-09-01Aiheet: Hae kokoteksti
Artikkeli -
9
PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
Julkaistu 2015-09-01Aiheet: Hae kokoteksti
Artikkeli -
10
APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
Julkaistu 2015-09-01Aiheet: Hae kokoteksti
Artikkeli -
11
The main causes and current principles of prevention of cardioembolic stroke
Julkaistu 2015-12-01Aiheet: Hae kokoteksti
Artikkeli